The United States Court of Appeals for the Federal Circuit has issued its decision in Rovi’s patent infringement litigation against Amazon Inc. Rovi (NASDAQ: ROVI) had sued Amazon in United States District Court for the District of Delaware in 2011 for infringing the two patents at issue in yesterday’s decision. The appeals court sided with Amazon and found that the District Court’s interpretation of the claims of the patents was correct and therefore Amazon did not infringe these patents. Rovi Corporation (NASDAQ:ROVI) shares after opening at $23.22 moved to $23.42 on last trade day and at the end of the day closed at $20.50. Company price to sales ratio in past twelve months was calculated as 3.68 and price to cash ratio as 3.79. Rovi Corporation (NASDAQ:ROVI) showed negative weekly performance of -13.06%.
Stock analysts at JMP Securities dropped their price target on shares of Cornerstone OnDemand (NASDAQ:CSOD) from $70.00 to $41.03 in a report issued on Tuesday, Analyst Ratings Network reports. JMP Securities’ target price would indicate a potential downside of 7.17% from the company’s current price. Cornerstone OnDemand, Inc. (NASDAQ:CSOD) shares fell -9.84% in last trading session and ended the day on $39.85. CSOD return on equity ratio is recorded as -80.20% and its return on assets is -11.40%. Cornerstone OnDemand, Inc. (NASDAQ:CSOD) yearly performance is 23.15%.
The Spectranetics Corporation (Nasdaq:SPNC) announced preliminary results for the three months ended March 31, 2014. The company will provide a full report on the financial results for the first quarter of 2014, and conduct a conference call with investors, on April 23, 2014. Spectranetics expects to report the following results for its first quarter of 2014, all compared with the three months ended March 31, 2013: Revenue of $39.6 million, up 5%,Vascular Intervention revenue grew 16%, led by U.S. peripheral atherectomy revenue growth of 29%. The Spectranetics Corporation (NASDAQ:SPNC) shares moved up -11.87% in last trading session and was closed at $23.01, while trading in range of $22.00-$24.20. The Spectranetics Corporation (NASDAQ:SPNC) year to date performance is -7.96%.
We continue to execute on our strategy of developing an ophthalmology-focused pipeline with greater financial strength,” said Dr. Irach Taraporewala, CEO of OHR Pharmaceutical Inc (NASDAQ:OHRP). “This financing provides us with the necessary resources to continue our clinical development programs, and seek out additional innovative ophthalmic candidates. We expect to complete enrollment in the OHR-002 wet-AMD study and initiate two randomized, controlled investigator sponsored trials to evaluate Squalamine eye drops for the treatment of diabetic macular edema early in the current quarter. Interim data on the OHR-002 study is expected in the second calendar quarter of 2014, with final data on the study available in the first quarter of calendar 2015. OHR Pharmaceutical Inc (NASDAQ:OHRP) weekly performance is -28.80%. On last trading day company shares ended up $9.84. OHR Pharmaceutical Inc (NASDAQ:OHRP) distance from 50-day simple moving average is -32.98%. Analysts mean target price for the company is $21.00.